Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Administration study of anti-doping target drugs in healthy adults
jRCT1071230045Completed
- Sponsor
- LSI Medience Corporation
- Start
- Jul 2023
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of roxadustat, enarodustat, daprodustat, molidustat, vadadustat and 4 more (10 arms), sponsored by LSI Medience Corporation. Primary endpoint: Effects of sample collection method. Started Jul 2023; status: completed.
02
Drugs
roxadustatenarodustatdaprodustatmolidustatvadadustat
Beyond the preview
Go deeper on jRCT1071230045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071230045.